Biopharmaceutical company developing kinase inhibitor therapies for cancers and other diseases.
Deciphera Pharmaceuticals, Inc. is a pioneering biopharmaceutical company dedicated to advancing the discovery, development, and commercialization of therapies aimed at enhancing the quality of life for cancer patients worldwide. Established in 2003 and headquartered in Waltham, Massachusetts, the company focuses on addressing critical unmet medical needs in oncology through innovative treatments.
At the forefront of Deciphera's portfolio is QINLOCK, its leading drug candidate designed to treat gastrointestinal stromal tumors (GIST). QINLOCK has demonstrated efficacy in both the treatment of GIST and is currently being evaluated in the INTRIGUE Phase 3 study as a second-line therapy for GIST patients, highlighting the company's commitment to improving outcomes for this patient population.
In addition to QINLOCK, Deciphera Pharmaceuticals is actively developing vimseltinib, an orally administered switch-control kinase inhibitor targeting the colony stimulating factor 1 receptor (CSF1R). This candidate shows promise in treating tenosynovial giant cell tumors (TGCT), a rare and debilitating condition for which effective treatments are limited.
Further expanding its therapeutic pipeline, the company is advancing DCC-3116 in combination with inhibitors targeting the RTK/RAS/MAP kinase signaling pathway. This approach aims to address RAS/RAF mutant cancers, underscoring Deciphera's strategy to leverage innovative science and strategic partnerships to advance novel treatment options in oncology.